FDA clears Nidek's OPD (Optical Path Difference)-Scan system:
This article was originally published in Clinica
Executive Summary
Nidek has received US FDA 510(k) marketing clearance for its stand-alone device for generating refractive eye maps. The OPD (Optical Path Difference)-Scan diagnostic system can create refractive power maps that show the total optical system aberrations within both eyes, claims the Fremont, California company. The product allows doctors to use one machine to create comprehensive, refractive power maps that are normally produced using at least two tests on two different machines, says Nidek's general manager and vice-president, Hiroshi Okada.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.